http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
SPG 유화법을 사용하여 현탁중합한 코어-쉘 구조를 갖는 열팽창 마이크로캡슐 제조
부지현(Ji Hyun Bu),김영선(Yeongseon Kim),하진욱(Jin Uk Ha),심상은(Sang Eun Shim) 한국고분자학회 2015 폴리머 Vol.39 No.1
30-50 μm의 입도를 갖는 마이크로캡슐을 목표로 poly(acrylonitrile-co-methyl methacrylate)를 쉘로, n-octane을 코어로 하는 코어-쉘 구조의 열팽창 마이크로캡슐을 합성하였다. SPG 멤브레인 유화 후 현탁 중합하여 기존의 현탁 중합대비 균일한 입자를 합성하였다. 또한 네 가지 안정제 및 다섯 가지 가교제의 종류와 함량에 따른 캡슐의 합성을 진행하였다. Poly(vinyl alcohol)을 안정제로 하여 합성한 캡슐의 표면이 매끈하면서도 균일한 형태를 보였으며, 액체 탄화수소가 코어에 캡슐화된 양 또한 우수하였다. 또한 가교제로 1,4-butnaediol methacrylate (BDDMA)를 첨가했을 때 평균입경 36.8 μm의 입자가 균일하게 합성되었다. 또한 BDDMA를 0.05 mol% 함량으로 합성한 입자의 캡슐화 정도가 가장 우수하였다. With aiming to prepare microcapsules having a particle size of 30-50 μm, thermally expandable capsules with relatively uniform particle sizes consisting of a n-octane/poly(acrylonitrile-co-methyl methacrylate) core/shell structure were synthesized using SPG membrane emulsification and suspension polymerization. Four steric stabilizers and five crosslinking agents were employed. When poly(vinyl alcohol) as a stabilizer was used, the prepared capsules showed a smooth and regular morphology and the liquid hydrocarbon (n-octane) was well encapsulated in the core. When 1,4-butnaediol methacrylate (BDDMA) was used as a crosslinker, the uniform capsules with the average diameter of 36.8 μm were synthesized. The capsules prepared with 0.05 mol% BDDMA showed the best encapsulation efficiency.
Byeon, Yeongseon,Lee, Jeong-Won,Choi, Whan Soo,Won, Ji Eun,Kim, Ga Hee,Kim, Min Gi,Wi, Tae In,Lee, Jae Myeong,Kang, Tae Heung,Jung, In Duk,Cho, Young-Jae,Ahn, Hyung Jun,Shin, Byung Cheol,Lee, Young Jo American Association for Cancer Research 2018 Cancer Research Vol.78 No.21
<P>These findings demonstrate the efficacy of a novel, selective, two-in-one delivery system to overcome chemoresistance in epithelial ovarian cancer.</P><P>Chemotherapy is commonly used in the treatment of ovarian cancer, yet most ovarian cancers harbor inherent resistance or develop acquired resistance. Therefore, novel therapeutic approaches to overcome chemoresistance are required. In this study, we developed a hyaluronic acid-labeled poly(d,l-lactide-co-glycolide) nanoparticle (HA-PLGA-NP) encapsulating both paclitaxel (PTX) and focal adhesion kinase (FAK) siRNA as a selective delivery system against chemoresistant ovarian cancer. The mean size and zeta potential of the HA-PLGA-NP were 220 nm and -7.3 mV, respectively. Incorporation efficiencies for PTX and FAK siRNA in the HA-PLGA-NPs were 77% and 85%, respectively. HA-PLGA-NP showed higher binding efficiency for CD44-positive tumor cells as compared with CD44-negative cells. HA-PLGA (PTX+FAK siRNA)-NP caused increased cytotoxicity and apoptosis in drug-resistant tumor cells. Treatment of human epithelial ovarian cancer tumor models HeyA8-MDR (<I>P</I> < 0.001) and SKOV3-TR (<I>P</I> < 0.001) with HA-PLGA (PTX+FAK siRNA)-NP resulted in significant inhibition of tumor growth. Moreover, in a drug-resistant, patient-derived xenograft (PDX) model, HA-PLGA (PTX+FAK siRNA)-NP significantly inhibited tumor growth compared with PTX alone (<I>P</I> < 0.002). Taken together, HA-PLGA-NP acts as an effective and selective delivery system for both the chemotherapeutic and the siRNA in order to overcome chemoresistance in ovarian carcinoma.</P><P><B>Significance:</B> These findings demonstrate the efficacy of a novel, selective, two-in-one delivery system to overcome chemoresistance in epithelial ovarian cancer. <I>Cancer Res; 78(21); 6247–56. ©2018 AACR</I>.</P>
Kim, Yeongseon,Kim, Minjae,Seong, Hong-Gyu,Jung, Ji Young,Baeck, Sung-Hyeon,Shim, Sang Eun Elsevier 2018 Polymer Vol.148 No.-
<P><B>Abstract</B></P> <P>Amphiphile-assisted silica@graphite with a surface resistivity of 10<SUP>12</SUP> Ω·sq<SUP>−1</SUP> was prepared via a one-step process using either an Ostwald ripening agent (Triton-X) or a bridgemer (PEG) under mild conditions. The composites containing coated fillers showed advantages in terms of their thermal and electrical properties over those using mixture of fillers. The filler possessing optimal size of graphite was incorporated with various polymer matrices such as TPEE, PDMS, epoxy, or HDPE, all of which have different processing characteristics due to their inherent viscosities. Consequently, the silica@graphite incorporated composites were found to have a superior effect on thermal and electrical properties including conductivity, dissipation, stability, and resistivity than boron nitride or alumina filled composites with the conservation of the electrical insulating property above 10<SUP>10</SUP> Ω·sq<SUP>−1</SUP> for a filler loading of 0–30 vol%.</P> <P><B>Highlights</B></P> <P> <UL> <LI> There is an optimal graphite size, which is not too small and not too big, for ensuring the high thermal conductivity of the composite. </LI> <LI> The coated silica layer acts as an efficient barrier which insulates against the electrical flow and induces less phonon scattering than when hybrid fillers are used. </LI> <LI> Silica@graphite incorporated composites were found to have a superior effect on thermal and electrical properties including conductivity, dissipation, stability, and resistivity. </LI> </UL> </P> <P><B>Graphical abstract</B></P> <P>[DISPLAY OMISSION]</P>
Kim, Ga Hee,Won, Ji Eun,Byeon, Yeongseon,Kim, Min Gi,Wi, Tae In,Lee, Jae Myeong,Park, Yun-Yong,Lee, Jeong-Won,Kang, Tae Heung,Jung, In Duk,Shin, Byung Cheol,Ahn, Hyung Jun,Lee, Young Joo,Sood, Anil K. TaylorFrancis 2018 DRUG DELIVERY Vol.25 No.1
<P><B>Abstract</B></P><P>Angiogenesis plays an essential role in the growth and metastasis of tumor cells, and the modulation of angiogenesis can be an effective approach for cancer therapy. We focused on silencing the angiogenic gene PLXDC1 as an important factor for anti-angiogenesis tumor therapy. Herein, we developed PLXDC1 small interfering siRNA (siRNA)-incorporated chitosan nanoparticle (CH-NP/siRNA) coated with hyaluronic acid (HA) to target the CD44 receptor on tumor endothelial cells. This study aimed to improve targeted delivery and enhance therapeutic efficacy for tumor anti-angiogenesis. The HA-CH-NP/siRNA was 200 ± 10 nm in size with a zeta potential of 26.4 mV. The loading efficiency of siRNA to the HA-CH-NP/siRNA was up to 60%. The selective binding of HA-CH-NP/siRNA to CD44-positive tumor endothelial cells increased by 2.1-fold compared with that of the CD44 nontargeted CH-NP/siRNA. PLXDC1 silencing by the HA-CH-NP/siRNA significantly inhibited tumor growth in A2780 tumor-bearing mice compared with that in the control group (<I>p</I> < .01), and mRNA expression of PLXDC1 was significantly reduced in the HA-CH-NP/siRNA-treated group. Furthermore, treatment with HA-CH-NP/siRNA resulted in significant inhibition of cell proliferation (<I>p</I> < .001), reduced microvessel density (<I>p</I> < .001), and increased cell apoptosis (<I>p</I> < .001). This study demonstrates that HA-CH-NP/siRNA is a highly selective delivery platform for siRNA, and has broad potential to be used in anti-angiogenesis tumor therapy.</P>
Epidemiological investigations of animal bite cases in high-risk regions of rabies, 2015
( Jun-sun Park ),( Ji-hye Um ),( Yeongseon Lee ),( Su Yeon Kim ),( Hae Kyung Lee ) 대한인수공통전염병학회 2016 창립총회 및 학술대회 초록집 Vol.2016 No.1
Introduction: Domestic animal rabies has only occurred in risk regions restrictively up to 2013. However, other cases out of the risk regions were reported between year of 2012 and 2013. A total of 11 cases of them were detected in Suwon and Hwaseong cities. Meanwhile, no Human rabies has beenfound since 2005. The Centers for Disease and Prevention control, since 2011, has been monitoring animal biting cases through the National Animal Bite Patient Surveillance (NABPS) to strengthen rabies surveillance. Methods: The demographic details of animal bite victim`s (age, gender, district, season, etc), exposure status (primary reported cause of bite) and postexposure prophylaxis (PEP) and relationship between the victim and animal bite in NABPS. Target regions were divided into three regions in this study: i) high-riskregion where there was exposure to wild animals and animal bite cases were reported;ii) suspect-risk region which is near the high-risk areas and where it was highly probable tohave animal bite cases; iii) non-risk regions which were categorized into another group. Results: In 2015, 877 animal bite cases were reported to NABPS. Among these cases, 862 cases werereported in highrisk regions, 1 case was found in suspect-risk region, 3 cases camefrom non-risk regions, and 11 cases occurred in regions whose status are still not yetconfirmed. According to the classification by province, 484 cases were in Gyeonggiprovince, while 378 cases were in Gangwon province. The number of category III (single or multiple transdermal bites, scratches or contamination of mucous membrane with saliva) reported from any source during the study period totalled 144. Among patients who were in category III,80% of them wasconfirmed that they were promptly treated according to the guidelines onhuman rabies prevention and control. Therefore, it is very significant for animal bite patients tobe treated promptly so that they can have a chance of surviving. Conclusion: In recent years, no human cases were reported since 2005. Monitoring animal bite victims through NABPS system has an important role in controlling human rabies efficiently. We will educate residents in high-risk regions and staff in public and health care organization and contribute to leading this nation to rabies-free zone.